OCS
Oculis Holding AG
$12.61
-0.51 (-3.89%)
At close · Jul 16
Market Cap
$761.49M
Shares
60,388,073
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$12.61
Open$12.97
Day$12.32–13.21
52W$10.52–34.13
Avg vol 30d633K
Short int1.2M · 2.0% float · 2.0d
Short vol79%
Last earningsNov 5, 2026
DataMay 2021–Jul 2026
Up next
Next earnings call
Aug 6, 2026
Scheduled
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.7 · calm
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−32%
below
RSI (14)
36
neutral
MACD trend
Positive
52-week position
9%
near low
Momentum
relative strength
1-month return
+10%
trailing
6-month return
−53%
trailing
YTD return
−37%
this year
Relative strength
−62%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $19 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
4 of 57 funds reported for Jun 30 · net +248.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.96% of float · ▲ +7.3% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 3-yr high, broad support
Squeeze score
46
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
7.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−32%
Bearish
RSI (14)
36
Neutral
MACD trend
Positive
Bullish
52-week position
9%
Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $19 › 200d $22 — 200d above 50d
Institutional flow
Accumulating
4 of 57 funds reported for Jun 30 · net +248.3K sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
1.96% of float · ▲ +7.3% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
57 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $11
Now $13 · 9%
52-wk high $34
vs 200-day avg -44%
vs 50-day avg -32%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OCS
this stock
Oculis Holding AG
|
$761.49M | -36.9% | — | — | 2.0% |
|
ONC
BeOne Medicines Ltd.
|
$458.76B | +4.5% | +22179.2% | 933.6 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.36B | +7.2% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$71.18B | -11.9% | +20.8% | 16.6 | 3.3% |
|
ARGX
Argenx SE
|
$53.68B | +2.0% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OCS | -8.0% | +10.1% | -52.8% | -9.1% | -36.9% |
| SPY | -0.1% | +0.1% | +9.0% | +0.5% | +10.1% |
| vs SPY | -7.8% | +10.1% | -61.8% | -9.6% | -47.0% |